TargetBeta
CTSC
cathepsin C · also DPP1, PLS, PALS · Cathepsins
3 programs in company-led studies act on CTSC, from 3 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| verducatib | Boehringer Ingelheim | phase 3 | 217 running | – | the company's pipeline |
| brensocatibrule | Insmed | phase 3 | 171 running | – | NCIt |
| RSS0343 | Jiangsu HengRui Medicine | phase 2 | 43 running | – | the company's pipeline |
Conditions their studies are in
- Bronchiectasis, 3 programs
- Cystic Fibrosis, 2 programs
- Pulmonary Disease, Chronic Obstructive, 2 programs
- Asthma, 1 program
- Hidradenitis Suppurativa, 1 program
- Nasal Polyps, 1 program
- Renal Insufficiency, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 25, 2026brensocatib · Insmed · phase 3 · NCT07859007
- Dec 14, 2026verducatib · Boehringer Ingelheim · phase 3 · NCT07781631
- Nov 2027RSS0343 · Jiangsu HengRui Medicine · phase 2 · NCT06775340
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.